X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/new-data-to-be-presented-for-biomarins-voxzogo-vosoritide-in-children-with-hypochondroplasia-and-achondroplasia-at-the-american-college-of-medical-genetics-and-genomics-acmg-annual-clinical-genetics-meeting-302085829.html
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-biomarins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia-301963505.html
https://investors.biomarin.com/2023-09-21-BioMarin-to-Present-Data-Showing-Long-Term-Benefit-of-VOXZOGO-R-vosoritide-on-Growth-in-Children-with-Achondroplasia-at-2023-European-Society-for-Paediatric-Endocrinology-ESPE-Meeting
https://investors.biomarin.com/2023-09-15-BioMarin-Receives-Positive-CHMP-Opinion-in-Europe-to-Expand-Use-of-VOXZOGO-R-vosoritide-to-Treat-Children-Aged-4-Months-and-Older-with-Achondroplasia
https://endpts.com/biomarin-touts-voxzogo-sales-bump-in-q2-results-notes-temporarily-tight-supply/
https://investors.biomarin.com/2023-03-14-BioMarin-to-Share-Updated-Data-at-2023-American-College-of-Medical-Genetics-and-Genomics-ACMG-Meeting-Demonstrating-Commitment-to-Understanding-Long-Term-Benefit-of-VOXZOGO-R-in-Children-with-Achondroplasia
https://www.biopharmadive.com/news/biomarin-fda-review-delay-roctavian-gene-therapy/644331/
https://www.prnewswire.com/news-releases/fda-accepts-biomarins-supplemental-new-drug-application-to-expand-use-of-voxzogo-vosoritide-for-injection-to-treat-children-with-achondroplasia-under-the-age-of-5-301765021.html
https://investors.biomarin.com/2023-01-03-European-Medicines-Agency-Validates-Application-for-Extension-of-Indication-for-VOXZOGO-R-vosoritide-for-injection-to-Treat-Children-with-Achondroplasia-Under-the-Age-of-2
https://www.prnewswire.com/news-releases/biomarin-announces-the-ministry-of-health-labor-and-welfare-mhlw-in-japan-granted-approval-for-voxzogo-vosoritide-for-injection-for-the-treatment-of-children-with-achondroplasia-whose-growth-plates-are-not-closed-301572235.html
https://www.clinicaltrialsarena.com/news/biomarin-trial-voxzogo-achondroplasia/
https://www.fiercepharma.com/pharma/biomarin-eyes-profit-as-dwarfism-drug-launch-underway-hemophilia-gene-therapy-refiling-nears
https://www.prnewswire.com/news-releases/biomarin-receives-fda-approval-for-voxzogo-vosoritide-for-injection-indicated-to-increase-linear-growth-in-children-with-achondroplasia-aged-5-and-up-with-open-growth-plates-301429145.html
https://trialsitenews.com/biomarin-receives-fda-accelerated-approval-for-voxzogo-vosoritide-for-treating-children-with-achondroplasia-a-rare-genetic-disorder/
https://www.fiercepharma.com/pharma/biomarin-s-dwarfism-drug-voxzogo-scores-european-nod-for-young-children-awaits-looming-fda
https://www.ema.europa.eu/en/documents/overview/voxzogo-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/biomarin-completes-full-enrollment-in-phase-2-study-of-vosoritide-for-treatment-of-infants-and-young-children-with-achondroplasia-301239664.html
https://investors.biomarin.com/2020-11-02-Food-and-Drug-Administration-Accepts-BioMarins-New-Drug-Application-for-Vosoritide-to-Treat-Children-with-Achondroplasia
https://www.prnewswire.com/news-releases/food-and-drug-administration-accepts-biomarins-new-drug-application-for-vosoritide-to-treat-children-with-achondroplasia-301165431.html
https://www.prnewswire.com/news-releases/food-and-drug-administration-accepts-biomarins-new-drug-application-for-vosoritide-to-treat-children-with-achondroplasia-301165431.html
https://endpts.com/biomarin-submits-nda-for-controversial-achondroplasia-drug/
https://www.prnewswire.com/news-releases/european-medicines-agency-validates-biomarins-marketing-authorization-application-for-vosoritide-to-treat-children-with-achondroplasia-301111748.html
https://www.prnewswire.com/news-releases/european-medicines-agency-validates-biomarins-marketing-authorization-application-for-vosoritide-to-treat-children-with-achondroplasia-301111748.html
https://investors.biomarin.com/2020-07-23-BioMarin-Submits-Marketing-Authorization-Application-to-European-Medicines-Agency-for-Vosoritide-to-Treat-Children-with-Achondroplasia
https://investors.biomarin.com/2020-07-23-BioMarin-Submits-Marketing-Authorization-Application-to-European-Medicines-Agency-for-Vosoritide-to-Treat-Children-with-Achondroplasia
https://www.fiercebiotech.com/biotech/biomarin-s-dwarfism-drug-clears-phase-3-poised-for-2021-launch
Market Place
Share 
